PALO ALTO, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, announced today that Dr. William (Wei) Cao, Chief Executive Officer of the Company will discuss the Company's Phase IIb interim clinical data on its Rejoin TM human adipose-derived mesenchymal progenitor cell (haMPC) therapy for Knee Osteoarthritis (KOA) and its CAR-T cell therapy for cancer clinical development programs at the 2015 Annual Regen Med Investor Day to be held on Wednesday, March 25, 2015 at 11:20 AM EDT at the Metropolitan Club in New York City.
A live-streaming webcast of all panels and company presentations will be available at: http://www.arminvestorday.com/webcast. The Company's presentation will be published on the event's website shortly after the conference and will be posted on the Company's website at http://cellbiomedgroup.com/newsroom/.
Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day investor meeting provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The program includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how advanced therapies could impact the standard of care in key therapeutic areas. In addition to presentations by more than 30 leading companies from across the globe, the event includes dynamic, interactive panels featuring research analysts covering the space, key clinical opinion leaders and top company CEOs. These discussions will explore themes specific to cell and gene therapy such as commercialization, market access and pricing for breakthrough technologies, gene therapy delivery and upcoming milestones in the adoptive T-cell therapy space.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.